Olivier Lamy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8944898/publications.pdf

Version: 2024-02-01

172386 118793 4,111 97 29 62 citations h-index g-index papers 122 122 122 3705 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image. Journal of Bone and Mineral Research, 2014, 29, 518-530.	3.1	617
2	Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone, 2015, 78, 216-224.	1.4	362
3	TBS (Trabecular Bone Score) and Diabetes-Related Fracture Risk. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 602-609.	1.8	326
4	Clinical Features of 24 Patients With Reboundâ€Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. Journal of Bone and Mineral Research, 2017, 32, 1291-1296.	3.1	270
5	β-Lactam Monotherapy vs β-Lactam–Macrolide Combination Treatment in Moderately Severe Community-Acquired Pneumonia. JAMA Internal Medicine, 2014, 174, 1894.	2.6	203
6	Practice and complications of liver biopsy. Digestive Diseases and Sciences, 1993, 38, 1480-1484.	1.1	151
7	Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 354-358.	1.8	146
8	Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporosis International, 2016, 27, 1923-1925.	1.3	122
9	Use of Trabecular Bone Score (TBS) as a Complementary Approach to Dual-energy X-ray Absorptiometry (DXA) for Fracture Risk Assessment in Clinical Practice. Journal of Clinical Densitometry, 2017, 20, 334-345.	0.5	113
10	Lumbar spine texture enhances 10-year fracture probability assessment. Osteoporosis International, 2014, 25, 2271-2277.	1.3	101
11	Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: A three-year study. Journal of Bone and Mineral Research, 2013, 28, 449-454.	3.1	88
12	Vertebral Fractures in Individuals With Type 2 Diabetes: More Than Skeletal Complications Alone. Diabetes Care, 2020, 43, 137-144.	4.3	82
13	The Trabecular Bone Score (TBS) Complements DXA and the FRAX as a Fracture Risk Assessment Tool in Routine Clinical Practice. Current Osteoporosis Reports, 2017, 15, 521-531.	1.5	78
14	Stopping Denosumab. Current Osteoporosis Reports, 2019, 17, 8-15.	1.5	77
15	Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases. Journal of Bone and Mineral Research, 2020, 36, 1717-1728.	3.1	61
16	Trabecular bone score in type 1 diabetesâ€"a cross-sectional study. Osteoporosis International, 2016, 27, 127-133.	1.3	60
17	The lumbar spine age-related degenerative disease influences the BMD not the TBS: the Osteolaus cohort. Osteoporosis International, 2017, 28, 909-915.	1.3	56
18	Risks and benefits of percutaneous vertebroplasty or kyphoplasty in the management of osteoporotic vertebral fractures. Osteoporosis International, 2014, 25, 807-819.	1.3	52

#	Article	IF	CITATIONS
19	Effects of Exemestane and Tamoxifen Treatment on Bone Texture Analysis Assessed by TBS in Comparison With Bone Mineral Density Assessed by DXA in Women With Breast Cancer. Journal of Clinical Densitometry, 2014, 17, 66-71.	0.5	48
20	Menopausal Hormone Therapy Is Associated With Reduced Total and Visceral Adiposity: The OsteoLaus Cohort. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1948-1957.	1.8	46
21	Association Between Physical Activity Levels in the Hospital Setting and Hospital-Acquired Functional Decline in Elderly Patients. JAMA Network Open, 2020, 3, e1920185.	2.8	46
22	Clinical Performance of the Updated Trabecular Bone Score (TBS) Algorithm, Which Accounts for the Soft Tissue Thickness: The OsteoLaus Study. Journal of Bone and Mineral Research, 2019, 34, 2229-2237.	3.1	40
23	Comparing Bone Microarchitecture by Trabecular Bone Score (TBS) in Caucasian American Women with and Without Osteoporotic Fractures. Calcified Tissue International, 2014, 95, 201-208.	1.5	39
24	Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. Breast Cancer Research and Treatment, 2020, 179, 153-159.	1.1	38
25	Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. Swiss Medical Weekly, 2017, 147, w14484.	0.8	35
26	The added value of trabecular bone score to FRAXÂ $^{\odot}$ to predict major osteoporotic fractures for clinical use in Chinese older people: the Mr. OS and Ms. OS cohort study in Hong Kong. Osteoporosis International, 2017, 28, 111-117.	1.3	34
27	Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clinical and Experimental Research, 2022, 34, 695-714.	1.4	33
28	Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporosis International, 2022, 33, 2103-2136.	1.3	33
29	Hypercalcaemia of malignancy: an undiagnosed and undertreated disease. Journal of Internal Medicine, 2001, 250, 73-79.	2.7	32
30	Full-Course Oral Levofloxacin for Treatment of Hospitalized Patients with Community-Acquired Pneumonia. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 82-88.	1.3	32
31	2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss Medical Weekly, 2020, 150, w20352.	0.8	28
32	Major depressive disorder in the general hospital: adaptation of clinical practice guidelines. General Hospital Psychiatry, 2003, 25, 185-193.	1.2	27
33	Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports. Osteoporosis International, 2019, 30, 1111-1115.	1.3	26
34	The Benefit of Menopausal Hormone Therapy on Bone Density and Microarchitecture Persists After its Withdrawal. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 5004-5011.	1.8	25
35	What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture?. Clinical Rheumatology, 2013, 32, 219-223.	1.0	24
36	Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis. Osteoporosis International, 2019, 30, 1125-1135.	1.3	23

3

#	Article	IF	Citations
37	Response to Letter: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2112-2112.	1.8	21
38	Cohort Profile: The OsteoLaus study. International Journal of Epidemiology, 2019, 48, 1046-1047g.	0.9	21
39	Intravenous ibandronate in men with osteoporosis: An open pilot study over 2 years. Journal of Endocrinological Investigation, 2003, 26, 728-732.	1.8	18
40	Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. European Respiratory Journal, 2004, 24, 644-648.	3.1	18
41	Breast Plasmacytoma. Leukemia and Lymphoma, 2000, 37, 611-615.	0.6	17
42	Underestimation of Vertebral Fractures After Denosumab Discontinuation. Journal of Bone and Mineral Research, 2018, 33, 547-547.	3.1	17
43	Effectiveness of a transition plan at discharge of patients hospitalized with heart failure: a beforeâ€andâ€after study. ESC Heart Failure, 2018, 5, 657-667.	1.4	17
44	Predictors and Implications of Early Clinical Stability in Patients Hospitalized for Moderately Severe Community-Acquired Pneumonia. PLoS ONE, 2016, 11, e0157350.	1.1	16
45	Clinical management of immunocompetent hospitalized patients with community-acquired pneumonia. European Journal of Internal Medicine, 2004, 15, 28-34.	1.0	15
46	Hypercalcaemia and acute renal failure after major burns: An under-diagnosed condition. Burns, 2010, 36, 360-366.	1.1	15
47	High prevalence of hypovitaminosis D in a Swiss rheumatology outpatient population. Swiss Medical Weekly, 2011, 141, w13196.	0.8	15
48	Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective. Journal of Medical Economics, 2008, 11, 499-523.	1.0	14
49	Impact of level of expertise versus the statistical tool on vertebral fracture assessment (VFA) readings in cohort studies. Osteoporosis International, 2017, 28, 523-527.	1.3	14
50	Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation. Case Reports in Rheumatology, 2018, 2018, 1-4.	0.2	14
51	High Evening Cortisol Level Is Associated With Low TBS and Increased Prevalent Vertebral Fractures: OsteoLaus Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2628-2636.	1.8	13
52	Spontaneous Vertebral Fractures in Males with Osteoporosis After Denosumab Discontinuation. Journal of Clinical Rheumatology, 2021, 27, S581-S584.	0.5	13
53	The role of teriparatide in sequential and combination therapy of osteoporosis. Swiss Medical Weekly, 2014, 144, w13952.	0.8	13
54	Quantitative Ultrasound (QUS) in the Management of Osteoporosis and Assessment of Fracture Risk: An Update. Advances in Experimental Medicine and Biology, 2022, 1364, 7-34.	0.8	13

#	Article	IF	CITATIONS
55	Review on the Utility of Trabecular Bone Score, a Surrogate of Bone Micro-architecture, in the Chronic Kidney Disease Spectrum and in Kidney Transplant Recipients. Frontiers in Endocrinology, 2018, 9, 561.	1.5	11
56	A potential role of hypophosphatemia for diagnosing convulsive seizures: A caseâ€control study. Epilepsia, 2019, 60, 1580-1585.	2.6	11
57	Failure of intravenous antibiotic therapy of multiple temporal brain abscesses due to Propionibacterium acnes requiring temporal lobectomy. Journal of Infection, 1997, 34, 269-271.	1.7	10
58	An economic analysis of hormone replacement therapy for the prevention of fracture in young postmenopausal women. Expert Opinion on Pharmacotherapy, 2003, 4, 1479-1488.	0.9	9
59	Medication reconciliation in a Swiss hospital: methods, benefits and pitfalls. European Journal of Hospital Pharmacy, 2019, 26, 129-134.	0.5	9
60	Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review. Osteoporosis International, 2020, 31, 2485-2491.	1.3	9
61	Impact of a fracture liaison service on patient management after an osteoporotic fracture: the CHUV FLS. Swiss Medical Weekly, 2018, 148, w14579.	0.8	9
62	Hypercalcemia of Malignancy. American Journal of Cancer, 2002, 1, 277-292.	0.4	8
63	Severe hypercalcemia after a single high dose of vitamin D in a patient with sarcoidosis. Rheumatology International, 2013, 33, 2955-2956.	1.5	8
64	Diurnal Salivary Cortisol in Sarcopenic Postmenopausal Women: The OsteoLaus Cohort. Calcified Tissue International, 2021, 109, 499-509.	1.5	8
65	Acquired hemophilia as first manifestation of breast carcinoma in a man under long-term spironolactone therapy. International Journal of Clinical Oncology, 2004, 9, 130-133.	1.0	7
66	Recommendations for raloxifene use in daily clinical practice in the Swiss setting. European Spine Journal, 2012, 21, 2407-2417.	1.0	7
67	Can one or two high doses of oral vitamin D3 correct insufficiency in a non-supplemented rheumatologic population?. Osteoporosis International, 2013, 24, 495-500.	1.3	7
68	"Inflammaging―and bone in the OsteoLaus cohort. Immunity and Ageing, 2020, 17, 5.	1.8	7
69	Thyroid-stimulating hormone is associated with trabecular bone score and 5-year incident fracture risk in euthyroid postmenopausal women: the OsteoLaus cohort. Osteoporosis International, 2022, 33, 195-204.	1.3	7
70	The fracture predictive ability of lumbar spine BMD and TBS as calculated based on different combinations of the lumbar spine vertebrae. Archives of Osteoporosis, 2022, 17, .	1.0	7
71	Calcium revisited: part II calcium supplements and their effects. BoneKEy Reports, 2014, 3, 579.	2.7	6
72	Reproducibility of Vertebral Fracture Assessment Readings From Dual-energy X-ray Absorptiometry in Both a Population-based and Clinical Cohort: Cohen's and Uniform Kappa. Journal of Clinical Densitometry, 2015, 18, 233-238.	0.5	6

#	Article	IF	CITATIONS
73	Correlation study between osteoporosis and hematopoiesis in the context of adjuvant chemotherapy for breast cancer. Annals of Hematology, 2018, 97, 309-317.	0.8	6
74	Meningitis due to non-steroidal anti-inflammatory drugs: an often-overlooked complication of a widely used medication. BMJ Case Reports, 2019, 12, e231619.	0.2	6
75	Postmenopausal women with osteoporosis consume high amounts of vegetables but insufficient dairy products and calcium to benefit from their virtues: the CoLaus/OsteoLaus cohort. Osteoporosis International, 2020, 31, 875-886.	1.3	6
76	Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry. Antiviral Therapy, 2015, 20, 261-269.	0.6	5
77	Unknown osteoporosis in older patients admitted to post-acute rehabilitation. Aging Clinical and Experimental Research, 2020, 32, 1145-1152.	1.4	5
78	Heart failure and community-acquired pneumonia: cases for home hospital?. International Journal for Quality in Health Care, 2001, 13, 301-307.	0.9	3
79	Morphometric Vertebral Assessments via the Use of Dual X-ray Absorptiometry for the Evaluation of Radiographic Damage in Ankylosing Spondylitis: A Pilot Study. Journal of Clinical Densitometry, 2014, 17, 190-194.	0.5	3
80	Increased Risk of Multiple Spontaneous Vertebral Fractures at Denosumab Discontinuation Must Be Taken Into Account. Journal of Clinical Oncology, 2020, 38, 1641-1642.	0.8	3
81	Non-invasive aspergillosis of the paranasal sinuses: CT and MRI findings. European Radiology, 1995, 5, 160-164.	2.3	2
82	Pancreatitis, hypereosinophilia and bilateral pulmonary infiltrates as presentation of acute Q fever. New Microbes and New Infections, 2021, 43, 100940.	0.8	2
83	Body composition and maximal exercise capacity after heart transplantation. ESC Heart Failure, 2022, 9, 122-132.	1.4	2
84	Risk Factors, Manifestation, and Awareness of Osteoporosis among Patients of Various Specialists in Switzerland: Results of a National Survey. Healthcare (Switzerland), 2022, 10, 295.	1.0	2
85	Bone Texture Assessment on Lateral VFAs Using the Texture Research Investigational Platform (TRIP) and its Fracture Discrimination Ability. Journal of Clinical Densitometry, 2022, 25, 599-605.	0.5	2
86	Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women. Annals of Internal Medicine, 2017, 167, 900.	2.0	1
87	Response to Letter to the Editor: "Menopausal Hormone Therapy Is Associated With Reduced and Total Visceral Adiposity: The OsteoLaus Cohortâ€, Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4035-4036.	1.8	1
88	Letter to the Editor: "Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline― Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3535-3536.	1.8	1
89	Bisphosphonates as a Firstâ€Line Treatment for Glucocorticoidâ€Induced Osteoporosis: Comment on the Article by Saag et al. Arthritis and Rheumatology, 2019, 71, 1770-1771.	2.9	1
90	Deep learning spine segmentation to get accurate and relevant BMD and TBS values: The OsteoLaus study. Bone Reports, 2020, 13, 100355.	0.2	1

#	Article	IF	Citations
91	Commentary to "Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials―(Galvano et al. J Bone) Tj ETQ	q11100.78	43 1 4 rgBT /C
92	Baseline Patient Characteristics of A Prospective Observational Study to Evaluate the Care Map of Women With Postmenopausal Osteoporosis (Pmo) in Switzerland (Campos). Value in Health, 2014, 17, A389.	0.1	0
93	Response to the Letter by Trovas. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1087.	1.8	O
94	The Metabolic Benefits of Menopausal Hormone Therapy Are Not Mediated by Improved Nutritional Habits. The OsteoLaus Cohort. Nutrients, 2019, 11, 1930.	1.7	0
95	Denosumab in early-stage breast cancer. Lancet Oncology, The, 2019, 20, e233.	5.1	0
96	PB1986 BLOOD CELL PRODUCTION IS NOT INFLUENCED BY BONE HEALTH STATUS IN HOMOEOSTASIS - THE COLAUS/OSTEOLAUS COHORT. HemaSphere, 2019, 3, 900-901.	1.2	0
97	Association of adiposity evaluated by anthropometric, BIA, and DXA measures with cardiometabolic risk factors in nonobese postmenopausal women. Menopause, 2022, Publish Ahead of Print, 450-459.	0.8	0